Acting as the compass for innovation, Ypsomed’s regulatory strategy steers ideas through development to deliver safe, compliant solutions to patients worldwide.
Wearable injectors come in many shapes and concepts. Our latest blog explores this diversity, and shows how YpsoDose stands out with consistent injection and minimal residual volume in large-volume self-injection.
SmartPilot is a digital add-on that transforms the YpsoMate autoinjector into a connected device. It automatically captures injection data, transmits it into the digital ecosystem, and transforms it into insights for patients, healthcare …
Discover the patient-driven design behind YpsoDose, our wearable patch injector for large-volume biologics. Learn how human factors shaped its intuitive, comfortable, and reliable use—simplifying self-injection for patients at home.
How did pen-inspired injectors evolve into today’s flexible self-injection platforms? Discover the trends in usability, scale-up, and resilient manufacturing that are shaping the future of drug delivery in a fast-changing industry landscape.
Subcutaneous injection or high-dose formulations requires optimized solutions. This joint article by Ypsomed and BD explores how YpsoMate 2.25 and BD Neopak™ syringes perform across a range of viscosities.
GLP-1 therapies are entering a high-growth phase, driving demand for scalable, sustainable delivery solutions. As formulations evolve, device usability, and environmental impact becomes a key industry challenge.
Whitepaper – How to establish clear measurable outcome metrics that align technology with therapeutic goals and couple robust data generation strategies with holistic patient experience and treatment efficacy.
Discover how Ypsomed’s innovative in-house assembly system streamlines workflows, enhances precision and slashes verification times, helping customers bring their products to market with speed and confidence.
What are the latest trends in large-volume drug delivery? A recent study explores key developments, while Ypsomed’s innovative injection platforms address the challenges of large volumes and high viscosities with patient-friendly solutions.
Discover how Ypsomed’s CE-certified reusable pens, ServoPen and YpsoPen, streamline market access. Our innovative platform model simplifies compliance, accelerates product availability, and provides comprehensive support to pharmaceutical partners at …
Discover how Ypsomed’s advanced delivery devices, including YpsoMate and YpsoDose, empower high-dose drug delivery. From viscosities to volumes, our innovative platforms transform patient care and enable pharmaceutical success. Explore the solutions …
How do patients handle pen injectors, and what forces do they apply during use? How can these findings shape the design of future devices to improve comfort and usability, especially for those with dexterity challenges?
Explore how Ypsomed is innovating subcutaneous drug delivery to meet the demands of high-viscosity and large-volume formulations.
Discover the latest innovation from Ypsomed: the YpsoMate 2.25 autoinjector, now configurated with an 8 mm needle. Designed to enhance patient comfort and injection efficiency, this new option continues our commitment to improving patient experiences …
Over the last 40 years, we have been at the forefront of the development and manufacturing of self-injection systems. How has Ypsomed transformed the market for platform-based self-injection devices?
White paper – Discover which business opportunities digital health solutions enable for pharmaceutical companies, starting from research and development, expanding to commercialisation through pre-launch, expansion, maturity and loss of exclusivity.
Article – Discover how digital health solutions make selfcare simpler and easier for patients while also facilitating research and development, market access and commercial success for pharmaceutical companies.
Ypsomed supplied first batches of YpsoMate 1 mL with a reduced carbon footprint as part of the NetZero Program in 2023 . This milestone is a key step in the transformation of the platform proven YpsoMate autoinjector into a zero-carbon emission …
To make sure people with visual and hearing impairments can use the YpsoMate autoinjectors without limitations, the devices are tested at METAS regarding the effectiveness of their acoustic signals.
Webinar recording – How to get the right mix of ingredients for digital health solutions to successfully reach market and scale while delivering long lasting value to patients.
Are you looking for digital health solutions that are adopted by patients at the start of therapy and keeps them on the therapy for as long as it is necessary? Dive into the latest insights from Ypsomeds’ Human Factors studies on digital health …
Innovative peptide hormone molecules for treating diabetes and obesity are fundamentally changing the market for self-injection systems and the demand for pens and autoinjectors continues to increase.
Immerse yourself in the future of subcutaneous drug administration with large-volume autoinjectors. Our comprehensive literature review reveals their transformative potential to break barriers in delivering single large-volume doses.
UnoPen and YpsoPen are two of Ypsomed’s platforms developed and customized on behalf of various pharma customers for patients dependent on insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has now exceeded the total of 100 million …
A message appears on Anna's smartphone; it's time for her next injection. The 19-year-old suffers from psoriasis and has to inject herself regularly with a medication. Anna is a little nervous, because the needle, the prick and the slight pain still …
In July 1921, Canadian researchers Frederick Banting and his assistant Charles Best achieved a revolutionary breakthrough: they succeeded in isolating insulin from dogs’ pancreas for the first time and were also able to demonstrate its blood …
.jpg)
